DBV Technologies SA (NAS:DBVT)
$ 3.9 0.835 (27.24%) Market Cap: 68.07 Mil Enterprise Value: 29.75 Mil PE Ratio: 0 PB Ratio: 1.32 GF Score: 39/100

DBV Technologies SA at Bank of America Merrill Lynch Health Care Conference Transcript

May 14, 2019 / 06:20PM GMT
Release Date Price: $89.9 (+5.39%)
Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP

Thank you for joining us at the Bank of America Merrill Lynch Conference. I'm Tazeen Ahmad. I'm the senior SMID biotech analyst. It's my pleasure to introduce the next company, DBV Technologies. Sitting next to me are 2 members from the management team, CEO, Daniel Tassé; and Chief Commercial Officer, Kevin Trapp. This will be a Q&A session, so please feel free to ask any questions you have.

But maybe, Daniel, as an introduction for those who may not know the company as well, maybe you can talk to us for a couple of minutes about DBV, its platform and kind of where you're at right now.

Daniel TassÃ;DBV Technologies S.A.;CEO;Director

©,-&

Absolutely. I can bellow or use your mic. Thank you. Good morning, all. My name is Daniel Tassé. I'm the CEO of DBV Technologies. We are a company that is looking at exploiting the extraordinary potential of epicutaneous tissues, essentially the skin, as an immune organ. The skin has incredible potential to simulate

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot